TGF-β regulates hepatocellular carcinoma progression by inducing treg cell polarization

Cellular Physiology and Biochemistry

Volumn 35, Issue 4, 2015, Pages 1623-1632

  Shen, Yinan ^a   Wei, Yongpeng ^a   Wang, Zhouchong ^a   Jing, Yingying ^a   He, Haiguan ^a   Yuan, Jianyong ^a   Li, Rong ^a   Zhao, Qiudong ^a   Wei, Lixin ^a   Yang, Tian ^a   Lu, Junhua ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

HCC; TGF ; Treg cells

Indexed keywords

DIETHYLNITROSAMINE; INTERLEUKIN 10; RECEPTOR BLOCKING AGENT; SM 16; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; AZABICYCLO DERIVATIVE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; GP73 PROTEIN, MOUSE; MEMBRANE PROTEIN; PHOSPHOPROTEIN; SM16 COMPOUND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL POLARITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICALLY INDUCED; CYTOLOGY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; LIVER TUMOR; METABOLISM; PATHOLOGY; UPREGULATION;

ANIMALS; AZABICYCLO COMPOUNDS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL POLARITY; CELL PROLIFERATION; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-10; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; PHOSPHOPROTEINS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84926362945     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000373976     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis b virus and hepatitis c virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-538.
3. Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM: Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010;52:921-929.
4. Zhang Z: Genomic landscape of liver cancer. Nat Genet 2012;44:1075-1077.
5. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010;140:883-899.
6. Chen DS, Mellman I: Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10.
7. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC: High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008;26:2707-2716.
8. Gao Y, Yao A, Zhang W, Lu S, Yu Y, Deng L, Yin A, Xia Y, Sun B, Wang X: Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Oncogene 2010;29:2784-2794.
9. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L: Increased intratumoral il-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009;50:980-989.
10. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF: Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol 2011;54:497-505.
11. Zhou L, Chong MM, Littman DR: Plasticity of cd4+ t cell lineage differentiation. Immunity 2009;30:646-655.
12. Vignali DA, Collison LW, Workman CJ: How regulatory t cells work. Nat Rev Immunol 2008;8:523-532.
13. Sakaguchi S, Yamaguchi T, Nomura T, Ono M: Regulatory t cells and immune tolerance. Cell 2008;133:775-787.
14. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old LJ, Wang RF: Cd8+ foxp3+ regulatory t cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007;13:6947-6958.
15. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W: Specific recruitment of regulatory t cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
16. Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF: Tumor-specific human cd4+ regulatory t cells and their ligands: implications for immunotherapy. Immunity 2004;20:107-118.
17. Gorelik L, Flavell RA: Transforming growth factor-beta in t-cell biology. Nat Rev Immunol 2002;2:46-53.
18. Chen W, Wahl SM: Tgf-beta: receptors, signaling pathways and autoimmunity. Curr Dir Autoimmun 2002;5:62-91.
19. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral cd4+cd25-naive t cells to cd4+cd25+ regulatory t cells by tgf-beta induction of transcription factor foxp3. J Exp Med 2003;198:1875-1886.
20. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA: A role for tgf-beta in the generation and expansion of cd4+cd25+ regulatory t cells from human peripheral blood. J Immunol 2001;166:7282-7289.
21. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM: Polarization of tumor-associated neutrophil phenotype by tgf-beta: "n1" versus "n2" tan. Cancer Cell 2009;16:183-194.
22. Heindryckx F, Mertens K, Charette N, Vandeghinste B, Casteleyn C, Van Steenkiste C, Slaets D, Libbrecht L, Staelens S, Starkel P, Geerts A, Colle I, Van Vlierberghe H: Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. Mol Cancer 2010;9:219.
23. Heindryckx F, Mertens K, Charette N, Vandeghinste B, Casteleyn C, Van Steenkiste C, Slaets D, Libbrecht L, Staelens S, Starkel P, Geerts A, Colle I, Van Vlierberghe H: Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. Mol Cancer 2010;9:219.
24. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, Haas A, Cheung HK, Zhang X, Corbley M, Kaiser LR, Ling L, Albelda SM: Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 2008;68:10247-10256.
25. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM: Polarization of tumor-associated neutrophil phenotype by tgf-beta: "n1" versus "n2" tan. Cancer Cell 2009;16:183-194.
26. Pickup M, Novitskiy S, Moses HL: The roles of tgfbeta in the tumour microenvironment. Nat Rev Cancer 2013;13:788-799.
27. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM: Gp73, a resident golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005;43:1007-1012.
28. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
29. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF: Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol 2011;54:497-505.
30. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L: Increased intratumoral il-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009;50:980-989.
31. Wang Y, Deng B, Tang W, Liu T, Shen X: Tgf-beta1 secreted by hepatocellular carcinoma induces the expression of the foxp3 gene and suppresses antitumor immunity in the tumor microenvironment. Dig Dis Sci 2013;58:1644-1652.
32. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G: Inhibition of transforming growth factor beta receptor i kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 2009;50:1140-1151.
33. Fransvea E, Mazzocca A, Antonaci S, Giannelli G: Targeting transforming growth factor (tgf)-betari inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 2009;49:839-850.
34. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P: The polarization of immune cells in the tumour environment by tgfbeta. Nat Rev Immunol 2010;10:554-567.
35. Zhu J, Paul WE: Cd4 t cells: fates, functions, and faults. Blood 2008;112:1557-1569.
36. Wu JF, Wu TC, Chen CH, Ni YH, Chen HL, Hsu HY, Chang MH: Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis b virus e antigen seroconversion. Gastroenterology 2010;138:165-172.
37. Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL, Wu JC, Lee PC, Chi CW, Lui WY, Lee SD: Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 2007;33:208-212.
38. Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W: A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer 2012;118:3984-3992.